Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TENUATE DOSPAN vs BONTRIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Releases norepinephrine from nerve terminals in the lateral hypothalamic feeding center, reducing appetite.
Bontril (phendimetrazine) is a sympathomimetic amine that acts as an appetite suppressant. Its mechanism involves stimulating the hypothalamus to release norepinephrine and dopamine, which reduces hunger cues. It is a prodrug that is metabolized to the active agent phenmetrazine, which inhibits reuptake and increases release of norepinephrine and dopamine in the central nervous system.
Short-term adjunct in exogenous obesity,FDA-approved for obesity management
FDA-approved for management of obesity as a short-term adjunct (few weeks) in a regimen of weight reduction based on caloric restriction, exercise, and behavior modification. Off-label uses are not well documented due to limited evidence.
25 mg orally three times a day, 1 hour before meals, or 75 mg extended-release orally once daily in the morning.
BONTRIL 50 mg orally once daily, with or without food.
The terminal elimination half-life is approximately 4-6 hours in adults with normal renal function, though clinical effects may last longer due to tissue distribution.
18-24 hours; prolonged in renal impairment (up to 40 hours) requiring dose adjustment.
Hepatic via CYP3A4 and other CYP enzymes
Phendimetrazine is extensively metabolized in the liver, primarily via N-demethylation to its active metabolite phenmetrazine. Minor pathways include hydroxylation and conjugation. Cytochrome P450 enzymes are involved, though specific isoforms are not fully characterized.
Renal excretion of unchanged drug and metabolites; approximately 85-90% of the dose is excreted in urine within 48 hours, with less than 5% in feces.
Primarily renal (60-70% unchanged) with minor biliary/fecal (10-15% as metabolites).
Approximately 20-30% bound to plasma proteins.
85-90% bound to albumin and alpha-1-acid glycoprotein.
Approximately 5-10 L/kg, indicating extensive tissue distribution.
3-5 L/kg; indicates extensive tissue distribution.
Rapidly absorbed from the gastrointestinal tract; absolute oral bioavailability is about 10-20% due to extensive first-pass hepatic metabolism.
Oral: 70-80% (first-pass metabolism); IV: 100%.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-59 m L/min), use with caution and consider dose reduction.
GFR >60 m L/min: no adjustment. GFR 30-60 m L/min: reduce dose to 25 mg once daily. GFR <30 m L/min: use is not recommended.
Contraindicated in severe hepatic impairment. For Child-Pugh A or B, use with caution and consider reducing dose to 12.5 mg twice daily.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose to 25 mg once daily. Child-Pugh Class C: use is contraindicated.
Not recommended for use in children under 12 years. For adolescents 12-17 years, same adult dosing may be used under strict supervision.
Weight-based: 1 mg/kg orally once daily, with a maximum of 50 mg. Not recommended for children weighing less than 10 kg.
Initiate at lower dose (12.5 mg twice daily) due to increased sensitivity and risk of adverse effects. Maximum dose 75 mg per day.
Start at 25 mg orally once daily; may increase to 50 mg after 2 weeks if tolerated and renal function is adequate (Cr Cl >60 m L/min).
None
None
Pulmonary hypertension,Valvular heart disease,Seizures,Psychiatric disturbances,Tolerance and dependence,May impair ability to drive or operate machinery
Risk of abuse, dependence, and tolerance; monitor for signs of addiction.,May cause serious cardiovascular events including pulmonary hypertension and valvular heart disease, especially with long-term use.,May impair ability to drive or operate machinery due to dizziness or blurred vision.,Use with caution in patients with hypertension, hyperthyroidism, glaucoma, or history of drug abuse.,Concomitant use with other sympathomimetics or MAO inhibitors can cause hypertensive crisis.,Not recommended for use in patients with a history of epilepsy or those taking other anorectic agents.
Advanced arteriosclerosis,Cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse,During or within 14 days of MAOI therapy
Known hypersensitivity to phendimetrazine or any component of the formulation.,History of cardiovascular disease including coronary artery disease, arrhythmias, or congestive heart failure.,Hypertension (moderate to severe).,Hyperthyroidism.,Glaucoma.,History of drug abuse or alcoholism.,Concurrent use of monoamine oxidase inhibitors or within 14 days of such use.,Pregnancy and breastfeeding.,Agitated states.,History of seizure disorders.
No specific food interactions. However, avoid excessive caffeine intake as it may increase stimulant effects. Take with or without food; high-fat meals may delay absorption.
Avoid high-fat meals as they may delay absorption of oral formulations. No specific food-drug interactions known; however, anticholinergic effects may be exacerbated by alcohol.
FDA Pregnancy Category X: Teratogenic effects demonstrated in animal studies; contraindicated in pregnant women due to increased risk of fetal malformations, particularly in the first trimester. Potential for neonatal withdrawal symptoms (hyperexcitability, feeding disorders) with third trimester exposure.
BONTRIL is classified as FDA Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and cleft palate. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and neonatal respiratory depression if used near term.
Excretion in human milk unknown; risk of serious adverse reactions in nursing infants (e.g., CNS stimulation, growth suppression). Use during breastfeeding contraindicated. M/P ratio not established.
No data available on excretion into human breast milk. M/P ratio unknown. Due to potential for serious adverse effects in nursing infants, breastfeeding is contraindicated during BONTRIL therapy.
No dose adjustment possible; drug contraindicated entirely during pregnancy due to known teratogenicity. If pregnancy occurs, discontinue immediately and manage with alternative therapy.
No dose adjustment required for pregnancy. However, due to teratogenicity, BONTRIL should be discontinued before conception or as soon as pregnancy is diagnosed.
TENUATE DOSPAN (diethylpropion) is a schedule IV controlled substance used as an adjunct in obesity management. Avoid concurrent use with MAOIs due to hypertensive crisis risk. Monitor for tachyphylaxis and potential for abuse; limit use to short-term (up to 12 weeks). Contraindicated in patients with hyperthyroidism, glaucoma, or history of drug abuse.
BONTRIL (hyoscyamine) is an anticholinergic used for GI spasms; avoid in patients with glaucoma, myasthenia gravis, or obstructive uropathy. Onset of action is 2-3 minutes IV; monitor for heat stroke in high ambient temperatures due to decreased sweating.
Take exactly as prescribed; do not increase dose or frequency.,Do not crush or chew the controlled-release tablet; swallow whole.,Report any chest pain, palpitations, or shortness of breath immediately.,Avoid alcohol and other CNS stimulants.,Use caution when driving or operating machinery until you know how this drug affects you.
Do not drive or operate machinery until you know how this medication affects you, as it may cause dizziness or blurred vision.,Avoid alcohol and other CNS depressants as they may increase sedation.,Report immediately if you experience eye pain, difficulty urinating, or rapid heartbeat.,Use caution in hot weather; this drug reduces sweating and increases risk of heat stroke.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TENUATE DOSPAN vs BONTRIL, answered by our medical review team.
TENUATE DOSPAN is a Sympathomimetic anorectic that works by Releases norepinephrine from nerve terminals in the lateral hypothalamic feeding center, reducing appetite.. BONTRIL is a Sympathomimetic Anorectic that works by Bontril (phendimetrazine) is a sympathomimetic amine that acts as an appetite suppressant. Its mechanism involves stimulating the hypothalamus to release norepinephrine and dopamine, which reduces hunger cues. It is a prodrug that is metabolized to the active agent phenmetrazine, which inhibits reuptake and increases release of norepinephrine and dopamine in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TENUATE DOSPAN and BONTRIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TENUATE DOSPAN is: 25 mg orally three times a day, 1 hour before meals, or 75 mg extended-release orally once daily in the morning.. The standard adult dose of BONTRIL is: BONTRIL 50 mg orally once daily, with or without food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TENUATE DOSPAN and BONTRIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TENUATE DOSPAN is classified as Category C. FDA Pregnancy Category X: Teratogenic effects demonstrated in animal studies; contraindicated in pregnant women due to increased risk of fetal malformations, particularly in the fi. BONTRIL is classified as Category C. BONTRIL is classified as FDA Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and cleft p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.